|
EP1395591B1
(en)
*
|
2001-06-12 |
2008-06-04 |
Glaxo Group Limited |
Corticotropin releasing factor antagonists
|
|
GB0117396D0
(en)
*
|
2001-07-17 |
2001-09-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2004062665A1
(en)
*
|
2003-01-16 |
2004-07-29 |
Sb Pharmco Puerto Rico Inc |
Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
GB0308208D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Glaxo Group Ltd |
Chemical compounds
|
|
MXPA05011710A
(es)
|
2003-05-05 |
2006-01-23 |
Hoffmann La Roche |
Derivados de pirimidina con actividad de crf.
|
|
ES2293317T3
(es)
*
|
2003-08-12 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
Derivados de tetrahidroquinazolina com antagonistas de cfr.
|
|
JP2007501822A
(ja)
|
2003-08-12 |
2007-02-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
コルチコトロピン放出性因子(crf)アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン
|
|
MY143499A
(en)
*
|
2003-12-22 |
2011-05-31 |
Sb Pharmco Inc |
Crf receptor antagonist and methods relating thereto
|
|
EP1701961A1
(en)
*
|
2004-01-06 |
2006-09-20 |
Taisho Pharmaceutical Co., Ltd |
Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
|
|
WO2005085253A1
(en)
*
|
2004-03-05 |
2005-09-15 |
Taisho Pharmaceutical Co., Ltd. |
Pyrrolopyrimidine derivatives
|
|
CA2569016C
(en)
|
2004-06-02 |
2012-11-27 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
|
AU2005257486A1
(en)
*
|
2004-06-25 |
2006-01-05 |
Taisho Pharmaceutical Co., Ltd. |
Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as CRF antagonists
|
|
GB0519957D0
(en)
*
|
2005-09-30 |
2005-11-09 |
Sb Pharmco Inc |
Chemical compound
|
|
US7652035B2
(en)
*
|
2004-10-19 |
2010-01-26 |
Neurocrine Bioscience, Inc. |
CRF receptor antagonists and methods relating thereto
|
|
US8088779B2
(en)
*
|
2005-09-30 |
2012-01-03 |
Smithkline Beecham (Cork) Limited |
Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
US8063050B2
(en)
*
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
ATE523499T1
(de)
*
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
EP2043744A2
(en)
*
|
2006-07-13 |
2009-04-08 |
SmithKline Beecham Corporation |
Chemical compounds
|
|
DE102007004303A1
(de)
|
2006-08-04 |
2008-02-07 |
Osram Opto Semiconductors Gmbh |
Dünnfilm-Halbleiterbauelement und Bauelement-Verbund
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
CN101918373B
(zh)
*
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
EP2240455B1
(en)
*
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
ES2422733T3
(es)
*
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
|
WO2009107767A1
(ja)
*
|
2008-02-29 |
2009-09-03 |
大日本住友製薬株式会社 |
H4受容体アンタゴニスト作用を有する新規2環性ピリミジン誘導体
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
RU2013148817A
(ru)
|
2011-04-01 |
2015-05-10 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и мек и способы их применения
|
|
WO2012135781A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
PL2748166T3
(pl)
|
2011-08-23 |
2019-05-31 |
Asana Biosciences Llc |
Związki pirimido-pirydazynonowe oraz ich zastosowanie
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
WO2014145576A2
(en)
|
2013-03-15 |
2014-09-18 |
Northwestern University |
Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN104193745B
(zh)
*
|
2014-07-30 |
2016-09-28 |
斯芬克司药物研发(天津)股份有限公司 |
一种咪唑并嘧啶羧酸类化合物及其制备方法
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CN118105392A
(zh)
|
2017-04-28 |
2024-05-31 |
自由生物有限公司 |
治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3774739B1
(en)
|
2018-04-09 |
2022-05-11 |
RaQualia Pharma Inc. |
Fused cyclic urea derivatives as crhr2 antagonist
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4161523A4
(en)
*
|
2020-06-03 |
2024-07-03 |
Yumanity Therapeutics, Inc. |
BICYCLIC HETEROARENES AND METHODS OF USE THEREOF
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|